Wegovy vs Mounjaro vs Ozempic: A Complete UK Comparison Guide
In the UK, where obesity affects over a quarter of adults, weight-loss injections have become a major talking point. If you’re searching for Wegovy or Mounjaro options, or wondering “Is Mounjaro better than Wegovy?” This guide explains everything clearly.
Drawing on NHS guidance, NICE approvals, and clinical trials, we compare these popular treatments factually. Remember, these are not instant fixes – they work best alongside lifestyle changes, and eligibility criteria matter.
1. Why Weight-Loss Injections Are Growing in the UK
Weight-loss injections are gaining visibility everywhere – from celebrity endorsements to GP waiting rooms. In 2025, sales of medicines such as Monjaro and Wegovy surged sevenfold to 2.5 million packs, with around 4% of UK households trying them.
Why the sudden rise?
- They are backed by strong clinical evidence
- Trials show up to 20% total body weight loss, far beyond diet alone
- They may improve heart health, reducing stroke and cardiac risks
- Demand is growing as supply shortages ease
Across online forums, people across North West England are increasingly searching for “Mounjaro near me” in St Helens, Wigan, Trafford, Northwich, Crewe, Staffordshire and Bolton as access continues to improve. It is not just about appearance – health benefits are a key driver. However, demand continues to outstrip supply at times, so patience (or private treatment) may be needed.
2. Wegovy vs Ozempic vs Mounjaro: What’s the Difference?
Wegovy and Ozempic
- Both contain semaglutide
- They differ in licensing and purpose
- Wegovy is approved specifically for obesity and weight management
- Ozempic is licensed for type 2 diabetes, with weight loss as a secondary effect
Mounjaro
- Contains tirzepatide, not semaglutide
- Targets two hormone pathways, GLP-1 and GIP
- This dual action may provide additional effects on appetite, metabolism, and weight reduction
Purpose Summary
- Ozempic: Primarily for blood sugar control in diabetic patients; weight loss is a side effect
- Wegovy: Intended for weight management in people who are obese or overweight
- Mounjaro: Approved for diabetes originally, now authorised for weight loss in eligible adults
All three belong to the category of incretin-based treatments, but their approvals, dosing, and intended uses vary.
3. Which Medications Are Approved for Weight Loss in the UK?
Wegovy – YES
Licensed for obesity and overweight management. Not restricted to diabetes.
Mounjaro – YES
Tirzepatide has been authorised for adult weight management in people with obesity or in overweight adults with weight-related medical conditions.
Ozempic – NO
Although weight loss occurs, it is approved solely for type 2 diabetes. Using Ozempic only for weight management is considered off-label.
Also Read: Understanding Mounjaro and Wegovy
4. Comparing Weight-Loss Results: Wegovy vs Ozempic vs Mounjaro
Clinical trials show a clear hierarchy:
Mounjaro leads
- 20.2% average body weight loss over 72 weeks
- Larger reductions in waist circumference (over 5 cm more than Wegovy)
Wegovy
- 13.7% weight loss over 72 weeks
- Strong cardiovascular benefits
Ozempic
- 10–15% weight loss, depending on the dose
- Designed primarily for diabetes
Real-world NHS data reflects this trend: Mounjaro users commonly achieve 18–22% weight loss when combined with diet and lifestyle changes. The Starting BMI affects outcomes, with a higher BMI generally producing larger reductions.
5. Who Is Eligible for Wegovy, Ozempic or Mounjaro in the UK?
In the UK, eligibility for weight-loss injections such as Wegovy, Ozempic or Mounjaro generally applies to adults with a BMI of 30 or above, which is classified as obesity. Individuals with a BMI of 27 or higher may also be eligible if they have a weight-related health condition, including
- High blood pressure
- High cholesterol
- Sleep apnoea
- Cardiovascular disease
- Type 2 diabetes
Wegovy Eligibility
Requires obesity or being overweight with health complications, plus previous attempts at losing weight through diet and exercise.
Mounjaro Eligibility
Also depends on BMI and weight-related health conditions such as hypertension, sleep apnoea, diabetes, or cardiovascular issues.
Ozempic Eligibility
Ozempic should be used only for type 2 diabetes, with weight loss occurring as a secondary effect. It is not recommended solely for slimming.
6. Side Effects Comparison
Mounjaro
-
Nausea / Vomiting: Common (20–30%)
-
Diarrhoea / Constipation: Very common
-
Headache / Fatigue: Occasional
-
Serious (e.g., pancreatitis): <1%
Wegovy
-
Nausea / Vomiting: Common (15–25%)
-
Diarrhoea / Constipation: Very common
-
Headache / Fatigue: Occasional
-
Serious (e.g., pancreatitis): <1%
Ozempic
-
Nausea / Vomiting: Mild (10–20%)
-
Diarrhoea / Constipation: Common
-
Headache / Fatigue: Rare
-
Serious (e.g., pancreatitis): <1%
Most side effects improve after a few weeks as your body adapts to the medicine.
7. Private Weight-Loss Treatment in UK Pharmacies (Including Hollowood Chemists)
Many people choose private care to start treatment more quickly. At Hollowood Chemists, private consultations allow you to:
- Access treatment without long waits
- Compare Wegovy vs Mounjaro
- Understand Mounjaro weight-loss prices – here
- Learn how to use injections safely
- Receive ongoing pharmacist support throughout your treatment
Conclusion:
For UK patients seeking regulated weight-loss medication, Wegovy and Mounjaro are the approved choices
FAQs
1. Is Mounjaro better than Wegovy?
Trials suggest yes, with weight loss injection Mounjaro showing around 20% weight loss compared with Wegovy’s 14%. However, Wegovy has notable heart-protective benefits, so the best choice depends on your medical history. Your clinician will determine suitability.
2. Where can I get Mounjaro near me?
Mounjaro is available through selected community pharmacies and private providers across the UK. Hollowood Chemists branches in (St Helens, Wigan, Trafford, Northwich, Crewe, Clayton and Bolton) offer private weight-loss consultations where you can access Mounjaro following a medical assessment.
If stock is limited, the team can advise on availability and delivery timelines.
3. How quickly do Wegovy or Mounjaro start working?
Most people notice reduced appetite and smaller portion sizes within 1–2 weeks. Visible weight loss usually begins around weeks 3–4, with the most significant results occurring between months 3 and 6 as doses increase.
4. Can I get these medicines on the NHS?
Wegovy is available on the NHS for eligible patients. Mounjaro is being rolled out gradually and may have limited availability. Because of supply and eligibility restrictions, many people choose private treatment at Hollowood Chemists for faster access.
Find answers to common questions
Disclaimer: This content is provided for informational and educational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Always seek advice from a qualified healthcare professional, pharmacist, or GP if you have any questions or concerns about a medical condition or medication. Never disregard professional medical advice or delay seeking medical care because of information provided here.
